title: Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.
abstract: Combination antiretroviral therapy (CART) reduces the mortality and morbidity in HIV-infected patients. However, facial lipoatrophy (FLA) is one of the well-known side-effects of this treatment and subsequently imposes major problems for HIV-infected patients. In the last decade, ample experience has been obtained with both local therapeutic options as well as possible systemic treatment options. Soft tissue fillers are a relatively simple and efficient treatment option for FLA. Especially, the biodegradable semi-permanent fillers combine a good effect with durability and an acceptable safety profile. The best way to prevent or restrict the development of FLA remains the exclusion of thymidine analogue nucleoside reverse-transcriptase inhibitors from the CART schedule.
authors: Department of Dermatology, VU Medical Centre, Amsterdam, The Netherlands.
authors: J A
authors: JA
authors: Kadouch
authors: L
authors: L
authors: van Rozelaar
authors: R B
authors: RB
authors: Karim
authors: R
authors: R
authors: Hoekzema
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D005145:Face; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced* / Q000628:therapy*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors
keywords: AIDS; CART-induced lipoatrophy; HIV; antiretroviral therapy; face; facial lipoatrophy; fillers; lipodystrophy; toxicity; treatment methods